- Previous Rank401
- Revenues ($M)7,670
- Revenue Percent Change18.1%
- Profits ($M)2,000
- Profits Percent Change37.9%
- Market Value (as of March 31, 2015)92,292
The biopharmaceutical company is the maker of Thalomid and various other drugs that treat multimple myeloma, inflammatory diseases, and various forms of cancer.
Looking for leads, investment insights, or competitive intelligence?Buy Now
Company Info
| CEO | Mark J. Alles |
| Industry | Pharmaceuticals |
| Sector | Health Care |
| HQ Location | Summit, NJ |
| Website | http://www.celgene.com |
| Years on List | 4 |
Key Financials (last fiscal year)
| $ millions | % change | |
|---|---|---|
| Revenues ($M) | 7,670 | 18.1% |
| Profits ($M) | 2,000 | 37.9% |
| Total Stockholder Equity | 6,525 | - |
| Employees | 6,012 | - |
| Market Value (as of March 31, 2015) | 92,292 | - |
Profit Ratios
| Profit as % of Revenues | 26.1% |
| Profits as % of Assets | 11.5% |
| Profits as % of Stockholder Equity | 30.7% |
Earnings Per Share (last fiscal year)
| Earnings Per Share ($) | 2.39 |
| EPS % Change (from 2013) | 41.8% |
| EPS % Change (5 year annual rate) | 23.6% |
| EPS % Change (10 year annual rate) | 40.9% |
Total Return
| Total Return to Investors (2014) | 32.4% |
| Total Return to Investors (5 year, annualized) | 32.1% |
| Total Return to Investors (10 year, annualized) | 32.7% |
